Načítá se...
Targeting RNA helicase DHX33 blocks Ras‐driven lung tumorigenesis in vivo
Ras has been found to be mutated in 30% of non‐small cell lung cancers, and its mutation has been regarded as a causal factor underlying tumorigenesis. However, no successful medicine has been developed so far to inhibit Ras for lung cancer treatment. We have previously identified DHX33 as a Ras dow...
Uloženo v:
| Vydáno v: | Cancer Sci |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540983/ https://ncbi.nlm.nih.gov/pubmed/32767810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14601 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|